Beijing Biostar Doses First Patient in Phase III Trial of UTD2 for Advanced Breast Cancer

PUBT · 2d ago
Beijing Biostar Doses First Patient in Phase III Trial of UTD2 for Advanced Breast Cancer
  • Beijing Biostar Pharmaceuticals announced first patient dosing in its Phase III HER2-negative advanced breast cancer trial on Oct. 20, 2026.
  • The registration trial compares oral utidelone capsules (UTD2) plus capecitabine with injectable utidelone (UTD1) plus capecitabine in previously treated patients.
  • The study will assess whether the oral combination matches the injectable combination in delaying disease progression.
  • Phase II results already presented at the 2026 ASCO Annual Meeting showed comparable or slightly better efficacy than historical injectable-combination data.
  • The oral combination substantially reduced severe peripheral neuropathy, potentially improving tolerability while enabling at-home treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijing Biostar Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261020-12376940), on October 20, 2026, and is solely responsible for the information contained therein.